Skye Bioscience, Inc. (SKYE) Stock Price & Analysis
Skye Bioscience, Inc. (SKYE) fell 2.48% to USD 0.75 as of June 10, 2026 at 03:51 UTC, according to Nexqual real-time market data.
SKYE last closed at USD 0.77; the session ranged USD 0.73–0.8 on volume of 197,518 shares. Market capitalization is $26.39M, with a 52-week range of USD 0.57–5.75 (NGM). Source: Nexqual, June 10, 2026 at 03:51 UTC.
Key Statistics (as of June 10, 2026 at 03:51 UTC)
| Price | USD 0.75 |
|---|---|
| Change | ▼ 2.48% (down) |
| Previous Close | USD 0.77 |
| Open | USD 0.77 |
| Day Range | USD 0.73 – 0.8 |
| 52-Week Range | USD 0.57 – 5.75 |
| Volume | 197,518 shares |
| Market Cap | $26.39M |
| Exchange | NGM |
Technical Analysis (SKYE)
Nexqual's technical model rates SKYE "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:51 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.78 (neutral) |
| vs SMA50 | Below (USD 0.8) |
| MACD | -0.02 (negative) |
Analyst Ratings (SKYE)
Wall Street analysts rate SKYE "None" based on 7 analysts, with a mean price target of USD 7.71 (range USD 2–20), per Nexqual as of June 10, 2026 at 03:51 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 7.71 |
| High Target | USD 20 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 6 / 2 / 0 |
Earnings (SKYE)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.32 vs est -0.32 ▲ beat |
| 2025-12-31 | USD -0.37 vs est -0.31 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.32 ▼ miss |
| 2025-06-30 | USD -0.45 vs est -0.3 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:51 UTC.
Financials & Fundamentals (SKYE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -167.97% |
| Debt / Equity | 3.46 |
| Current Ratio | 1.78 |
| Total Cash | $17.11M |
| Total Debt | $311,318 |
| Free Cash Flow | $-21.13M |
Source: Nexqual, June 10, 2026 at 03:51 UTC.
Financial Health Score (SKYE)
Nexqual rates Skye Bioscience, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:51 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $17M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$42M |
| Efficiency | Critical — ROE -168%, ROA -87.7% |
Ownership (SKYE)
| Insider Ownership | +1.17% |
|---|---|
| Institutional Ownership | +46.00% |
| Shares Outstanding | 35.14M |
| Float | 22.96M |
| Short % of Float | +4.50% |
Source: Nexqual, June 10, 2026 at 03:51 UTC.
Leadership (SKYE)
Skye Bioscience, Inc. is led by Punit S. Dhillon B.A. (age 45), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:51 UTC.
| President, CEO & Director | Punit S. Dhillon B.A. (age 45) |
|---|---|
| Chief Operating Officer | Tu Diep M.Sc. (age 44) |
| CFO and Principal Financial & Accounting Officer | John P. Sharp (age 60) |
| Chief Scientific Officer | Christopher G. Twitty (age 53) |
Major Backers & Investors (SKYE)
Notable institutional backers of Skye Bioscience, Inc. include 5AM Venture Management, LLC, Versant Venture Management, LLC, Baker Bros. Advisors, LP, according to Nexqual as of June 10, 2026 at 03:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| 5AM Venture Management, LLC | 34.5% |
| Versant Venture Management, LLC | 7.15% |
| Baker Bros. Advisors, LP | 5.61% |
| Sphera Funds Management Ltd. | 2.42% |
| Millennium Management | 0.92% |
| Fidelity | 0.86% |
| Platinum Investment Management Ltd | 0.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.81% |
| BlackRock | 1.2% |
| Geode Capital | 0.99% |
Source: Nexqual, June 10, 2026 at 03:51 UTC.
From Skye Bioscience, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- In addition to injectable therapies for overweight and obesity, Wegovy became the first FDA approved oral GLP-1 receptor agonist in December 2025 and other oral therapies are in development for treating overweight and obesity, including those being development by Eli Lilly, Structure Therapeutics, and Viking Therapeutics.
- Halozyme will also be the Company's exclusive supplier of clinical and commercial supplies of the active pharmaceutical ingredient ("API") for Halozyme's rHuPH20 bulk drug product.
- Review and approval of drugs and biologics in the United States In the United States, the Food and Drug Administration ("FDA") regulates drugs under the Federal Food, Drug and Cosmetic Act (the "FDCA"), and its implementing regulations, and regulates biologics under the FDCA, the Public Health Service Act (the "PHSA"), and their implementing regulations.
- Intellectual Property The success of our product candidates will depend in large part on our ability to obtain and maintain patent and other legal protection for the proprietary technology, inventions and improvements we consider important to our business, prosecute our patent applications and defend any issued patents we obtain, preserve the confidentiality of our trade secrets, and operate without infringing the patents and proprietary rights of third parties.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACCL | Acco Group Holdings Limited | USD 1.52 | ▼ 1.94% |
| SLSN | Solesence, Inc. | USD 1.22 | ▼ 6.87% |
| NVEC | NVE Corporation | USD 105.17 | ▲ 3% |
| NGEN | NervGen Pharma Corp. | USD 1.81 | ▼ 2.69% |
| VECO | Veeco Instruments Inc. | USD 67.19 | ▲ 14.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:51 UTC. This page is informational and not investment advice.